Newsroom | 3872 results

DUBLIN--(BUSINESS WIRE)--The "Magnetic Resonance Imaging (MRI) Equipment - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. MRI systems remain a cornerstone in today’s medical imaging landscape, aiding in the diagnosis and management of various chronic conditions. These non-invasive devices are favoured for their precision and safety, significantly overshadowing ionizing radiation methods, despite certain limitations for patients with metallic implants and s...

LOS ANGELES--(BUSINESS WIRE)--The GRAMMY Museum® Grant Program announced today that $200,000 in grants will be awarded to 15 recipients in the United States to help facilitate a range of research on a variety of subjects, as well as support a number of archiving and preservation programs. "The GRAMMY Museum and Recording Academy® have continued their partnership to provide fundamental funding for music research and preservation projects across the United States and Canada. We are incredibly ins...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurol...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to partici...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2025...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be ac...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce la tenue de son Assemblée Générale Mixte le 13 mai 2025 à 14h00 au siège social de la Société, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. L’Assemblée Généra...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 13, 2025, at 2:00 pm CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast li...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data validating the accuracy and clinical utility of its AI-powered hyperdensity measurement solution for intracranial hemorrhage (ICH) management. Two independent studies highlight the ability of Viz ICH Plus to accurately and efficiently measure hemorrhage volume, quantify lateral ventricular volume, and estimate midline shift. “Patients with ICH o...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced additional strategic partnership agreements (“SPAs”), bringing the total to 18 clinical sites engaged to advance Cybin’s multinational Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD...